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Background: Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in
infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high
risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of
hospitalisation with RSV in the United Kingdom (UK).
Methods: A decision tree model was developed to reflect the clinical pathway of infants at high risk of severe RSV
infection who receive either prophylaxis with palivizumab or no prophylaxis. The main outcome was the
incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed to assess
the degree of uncertainty surrounding the results. A threshold analysis considered the impact of clinical and
environmental risk factors on the cost-effectiveness in the subgroup of preterm infants 33–35 weeks gestational
age (wGA).
Results: Prophylaxis with palivizumab compared with no prophylaxis is associated with the following ICERs; £33,216
for infants with congenital heart disease; £19,168 for infants with chronic lung disease; £3,845 for preterm infants
< 29 wGA; £30,205 for preterm infants 29–32 wGA; and £99,056 for preterm infants 33–35 wGA. One-way sensitivity
analysis suggests that these results are highly sensitive to the input data. Threshold analysis in the preterm 33–35 wGA
subgroup demonstrates that an adjusted RSV-hospitalisation baseline risk of 17.94% or higher would result in an ICER
below the £30,000 per quality-adjusted life-year threshold.
Discussion: Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the
subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources.
Keywords: Palivizumab; Prophylaxis; Cost-effectiveness; Respiratory syncytial virus; United KingdomBackground
Human respiratory syncytial virus (RSV) is a common
virus that causes respiratory tract infections. In the United
Kingdom (UK) these infections usually occur between the
months of October to March and are characterised by a
relatively short epidemic of about six weeks [1]. In the
majority of cases, RSV infection is a mild and self-limiting
illness, however it can be severe enough to cause lower
respiratory tract infection (LRTI) requiring hospitalisation
in babies and infants and is associated with significant* Correspondence: Anthony.Bentley@abacusint.com
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in any medium, provided the original work is prespiratory morbidity including bronchiolitis, pneumonia
and even death [1,2]. 2-3% of infants aged < 1 year are
admitted to hospital annually with RSV bronchiolitis
[3]. Muller-Pebody et al. suggested that 17.5% of hospital
admissions for LRTIs and 74.8% of admissions for
unspecified bronchiolitis were caused by RSV. They
further suggested that 28.3/1000 hospital admissions
under one year of age were attributable to RSV [4]. Infants
with underlying medical conditions such as chronic lung
disease (CLD), congenital heart disease (CHD) or who
were born prematurely are particularly at increased risk of
complications from RSV infection, resulting in prolonged
hospitalisation, admission to intensive care and poorer
outcomes [5-7]. A 2003 UK cohort study found that ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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and < 6 months of age at the onset of RSV season or < 2
years of age with CLD needing home oxygen therapy, 9.2%
were re-hospitalised for RSV disease [3]. Furthermore,
there is evidence to suggest that severe LRTI in early
childhood may be associated with respiratory morbidity
such as recurrent wheeze and/or asthma in later childhood
and early adulthood, however mechanisms for this are
poorly understood [8,9]. It is well recognised that severe
RSV infection is associated with a significant health and
economic burden [10-15].
RSV is an RNA virus that is spread via respiratory
droplets from nasal secretions of infected individuals,
and the risk of infection increases in settings where
the chances of exposure are greater [14]. As the virus-
contaminated droplets can persist for several hours on
surfaces, the risk is particularly high in environments,
such as playgrounds, overcrowded housing, and hospitals
[14]. Evidence suggests that the majority of infants will
have been infected with RSV by the time they reach two
years of age [13]. Recurrent infection is frequent, however
it is thought that primary infections may provide some
protection against future severe disease [13,14]. Mild cases
of RSV are usually not formally diagnosed and treatment
involves self-care measures to relieve the symptoms
[13,14]. Severe cases may lead to hospitalisation and in
some cases admission to intensive care. To date there is
no effective treatment for RSV LRTI beyond supportive
care [13,14].
Palivizumab is a humanised monoclonal antibody
approved in Europe, and the only pharmacological
prophylaxis licensed in Europe, for the prevention of
serious LRTI requiring hospitalisation caused by RSV in
children at high-risk of RSV disease [7]. This includes
pre-term infants (≤ 35 weeks gestational age [wGA]
and aged under six months at the start of the RSV
season), infants under two years of age with CLD
requiring treatment for bronchopulmonary dysplasia
within the previous six months, and infants under
two years of age born with haemodynamically significant
CHD [13-15].
It is well established that palivizumab prophylaxis is an
effective and well tolerated approach to reducing the
incidence of LRTI requiring hospitalisation [5,6]. In
clinical trials, palivizumab has been shown to reduce
the overall incidence of RSV-associated hospitalisations
in high-risk pre-term infants and those with CLD and
CHD compared with placebo [16,17]. However, it is neces-
sary to evaluate the cost-effectiveness of healthcare inter-
ventions. Although studies have previously described
the cost-effectiveness of palivizumab in high-risk infant
groups [12-15], the conclusions have varied and concerns
have been raised regarding the data and assumptions used
within these analyses [18].This study re-evaluated cost-effectiveness of palivizumab
in the UK using updated data derived from clinical trials
and recent healthcare costs. The most influential parameters
and their impact on the incremental cost-effectiveness
ratio (ICER) have been investigated to provide a transparent
assessment.Methods
Outline of the economic model
A decision tree model was developed to reflect the clinical
pathway of infants at high risk of severe RSV infection
who either receive prophylaxis with palivizumab or no
prophylaxis. Baseline risk of RSV hospitalisations and
efficacy data were taken from palivizumab clinical trials.
The analysis was conducted from the perspective of the UK
National Health Service (NHS). Cost data were obtained
from national databases and published literature. The
main outcome was presented as the incremental cost per
quality-adjusted life-year (QALY) gained.
The population investigated were children at high risk of
RSV hospitalisation and its sequelae (chronic respiratory
morbidity); i.e. preterm infants (≤ 35 wGA and aged
under six months at the start of the RSV season), infants
(aged under 24 months) with CLD, and infants (aged under
24 months) with haemodynamically significant CHD.
These three main patient groups correspond to the
licensed indications for palivizumab in Europe [7].
The model illustrated in Figure 1 traces the pathway
of infants at high risk for severe LRTI for one year,
which corresponds to the RSV season (October-March in
the UK) and the period of clinical follow-up. The model
considers two scenarios for these high-risk infants. At the
start of the season, infants either receive prophylaxis with
palivizumab or no prophylaxis. The dosage of palivizumab
administered is estimated based on the infant weight at
the start of the season, using the clinical trial data [16,17],
and an assumed increase in weight each month based on
World Health Organisation (WHO) growth charts [19,20].
Both groups of infants may develop RSV infection leading
to hospitalisation. The majority of these children will be
managed in a paediatric ward, but some will require trans-
fer to the Intensive Care Unit (ICU). Of the hospitalised
infants, a very small proportion will die. Infants with a
hospitalisation due to RSV disease will be at increased risk
of developing chronic respiratory morbidity (sequelae).
The base case model considers that this morbidity is likely
to persist into early childhood, based on the studies by
Greenough et al., and Shefali-Patel et al., which looked
at the healthcare utilisation over two years in children
with CLD and late preterm infants, respectively, who had
RSV-proven infection requiring hospitalisation [21,22].
Both costs and outcomes were discounted at 3.5% in line
with National Institute for Health and Clinical Excellence
Figure 1 Decision tree model schematic.
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sensitivity analysis between 0% and 6.5%.
Data sources used in the analysis
The model input data are summarised in Table 1.
Clinical data
The following trials were identified to inform the clinical
input data: Feltes et al. [5] considered children under 24
months of age with haemodynamically significant CHD;
and the IMPACT RSV study [6], which analysed preterm
infants of ≤ 35 wGA and aged less than six months at
the onset of the RSV season and children under 24
months of age with or without CLD. Data from these
two randomised, controlled trials (RCTs) and additional
observational studies were used to inform clinical model
inputs (Table 1).
Probability of RSV hospitalisation
Data on RSV hospitalisation risk were derived from a
number of sources depending on the population subgroup
as described below:
CHD children: Feltes et al. [5] reported a 9.7% risk of
RSV hospitalisation among children with haemodynamic-
ally significant CHD who did not receive RSV prophylaxis
(versus a 5.3% risk in the palivizumab group) and showed
that the use of palivizumab for prophylaxis was associated
with a relative risk reduction of 45%.CLD children: The IMPACT RCT [6,17] found that
among premature infants and children with CLD who did
not receive RSV prophylaxis, the rate of RSV hospitalisa-
tion was 10.6% (versus 4.8% in the palivizumab group).
Overall, monthly prophylaxis with palivizumab resulted in
a 55% relative risk reduction of RSV hospitalisation. The
RSV hospitalisation rate was found to be 12.8% for the
subgroup of children with CLD who did not receive RSV
prophylaxis (versus 7.9% in the palivizumab group), with a
relative risk reduction of 39%.
Preterm < 29 wGA, 29–32 wGA and 33–35 wGA: The
baseline rate of RSV hospitalisation for the preterm infant
subgroups and the relative risk reduction associated with
palivizumab prophylaxis were obtained from retrospective
subgroup analysis of the preterm infants of the IMPACT
RCT [6,17]; this subgroup analysis is based on unpublished
data (MedImmune/Abbott, Data on File).
Probability of sequelae (recurrent wheeze asthma)
Data on the risk of RSV-related sequelae (RSV-associated
respiratory morbidity) were taken from two cohort studies
by Greenough et al. [21,24] and a study by Shefali-Patel
[22]. These studies demonstrated that in the cohort of
children with CLD [24] and 33–35 wGA babies [22] post
RSV hospitalisation, there was an increase in healthcare
resource use attributable to respiratory sequelae for a
two-year period [24], and a decrease in quality of life
experienced for five years [21]. Because the above
Table 1 Summary of input data used in the model
Subgroup Value (lower and upper CI) Reference
Baseline risk of hospitalisation
CHD infants 9.7% (7.4%, 12.0%)† Feltes et al. 2003 [5]
CLD infants 12.8% (8.8%, 16.8%)† IMPACT, 1998 [6]
Preterm: <29 wGA 10.00% (0.7%, 19.3%)† MedImmune/Abbott, Data on File.
Preterm: 29–32 wGA 7.69% (2.86%, 12.5%)† MedImmune/Abbott, Data on File.
Preterm: 33–35 wGA 7.69% (2.86%, 12.5%)† MedImmune/Abbott, Data on File.
Relative risk reduction of RSV hospitalisation with palivizumab prophylaxis
CHD infants 45.3% (18.1%, 63.4%)† Feltes et al. 2003 [5]
CLD infants 38.5% (5.0%, 60.2%)† IMPACT, 1998 [6]
Preterm: <29 wGA 80.39% (0.00%, 96.26%)† MedImmune/Abbott, Data on File.
Preterm: 29–32 wGA 79.69% (35.38%, 93.62%)† MedImmune/Abbott, Data on File.
Preterm: 33–35 wGA 73.16% (54.87%, 93.09%)† MedImmune/Abbott, Data on File.
Mortality rates of children hospitalised due to RSV disease
CHD infants 3.72% (1.19%, 6.23%)† Wang et al. 2008 [14]
CLD infants 4.00% (3.00%, 5.00%)† Wang et al. 2008 [14]
Preterm infants 0.43% (0.23%, 0.63%)† Wang et al. 2008 [14]
Life expectancy
CHD infants 76.0 years (75.0††, 78.9††)‡ Office for National Statistics [25]
All other subgroups 79.0 years (77.9††, 82.0††)‡ Office for National Statistics [25]
Risk of RSV-related sequelae
Increase in resource use 2 years Greenough et al. 2001 [24]
Decrease in utility 5 years Greenough et al. 2004 [21]
Drug and administration costs
Palivizumab (50 mg vial) £306.64/pack (£6.13/mg) MIMS [27]
Palivizumab (100 mg vial) £563.64/pack (£5.64/mg) MIMS [27]
Initial administration by hospital nurse £41 (£23, £47) Costs of Health and Social Care 2009–2010 [29]
Subsequent administration by GP practice nurse £31 (£26, £36) Costs of Health and Social Care 2009–2010 [29]
Rate of hospital admissions for RSV (% of patients)
CHD children in general ward 100% Assumption
CHD children in Intensive Care Unit (ICU) 38.14% (28.48%, 47.81%)† Feltes CSR [16]
All other infants; General ward 100% Assumption
All other infants; Intensive Care Unit (ICU) 27.45% (18.79%, 47.81%)† FDA - Palivizumab Clinical Review [2]
Length of stay of hospital admissions for RSV patients
CHD children in general ward 12.40 (9.30, 18.99§) ‡ FDA - Palivizumab Clinical Review [2]
CHD children in Intensive Care Unit (ICU) 15.19 (11.39, 15.50§)‡ FDA - Palivizumab Clinical Review [2]
All other infants; General ward 6.64 (4.98, 8.32§)‡ FDA - Palivizumab Clinical Review [2]
All other infants; Intensive Care Unit (ICU) 7.04 (5.28, 8.80§)‡ FDA - Palivizumab Clinical Review [2]
Cost per day of RSV hospitalisation
General ward £555¶ (£406*, £1,955*) NHS National Schedule of Reference Costs [28]
Intensive Care Unit (ICU) £2,225 ¶ (£311*, £1,954*) NHS National Schedule of Reference Costs [28]
Medical cost of sequelae (recurrent wheeze/asthma)
Annual per patient cost for all other subgroups £14, 015 Greenough et al., 2004 [21]; Costs of Health and
Social Care 2009–2010 [29]; NHS National Schedule
of Reference Costs [28]
Annual per patient cost for 33–35 wGA £810 (£0, £8,972) Shefali-Petal et al., 2011 [22]
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Table 1 Summary of input data used in the model (Continued)
Health state utility values (Utility (SE); (Lower and upper CI)
Non RSV-H patients 0.95 (0.25)†; (0.03, 1.00‡‡) Greenough et al., 2004 [21]
Patients admitted with RSV-H 0.88 – Modelled as 7.37% (0.94%)
reduction†; (5.53%, 9.21%§)
Greenough et al., 2004 [21]
Abbreviations: CI Confidence interval, CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, GP General practitioner, SE Standard
error, RSV-H Respiratory syncytial virus hospitalisation. †Beta distribution; ‡ Gamma distribution; Log-normal distribution. †† The lower and upper confidence
intervals are based on the average life expectancy of males and females respectively. § Estimated assuming a confidence interval of ± 25%. * Interquartile range.
‡‡ Plausible range.
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RSV hospitalisation, the model assumes that the two-
year increase in resource use and the five-year decrease
in utility are applied to all infants who experience an
RSV hospitalisation. No difference in the risk of sequelae
was assumed between those who received prophylaxis and
those who did not, as the RSV hospitalisation was a sole
determinant for development of respiratory sequelae.
Life expectancy for infants at risk of RSV infection and
probability of RSV-related mortality
The life expectancy for infants at risk of RSV infection
was calculated by averaging the life expectancies for
men and women, assuming an equal split, born today
using data from the Office of National Statistics [25].
The mean life expectancy was estimated to be 80.0 years
(standard error [SE]: 1.05). However, for the purposes of
this analysis the first year of life was captured in the
decision tree and so the remaining life expectancy for an
infant at the age of one year was assumed to be 79.0
years. In the case of children with CHD, 95.3% were
predicted to survive to age 16 years if they had survived
to age of one year [26]. Therefore, the life expectancy at
the age of one year was assumed to be 76.0 years for
children with CHD. The mortality rates (Table 1) were
as described in a recent health technology assessment by
Wang et al. [14], which forms the basis for the Joint
Committee on Immunisation and Vaccination (JCVI)
recommendations on the usage of palivizumab [1].
Drug cost data
The recommended dose of palivizumab is 15 mg per kg
body weight, injected intramuscularly, given once a
month during anticipated periods of RSV risk in the
community. The initial dose was calculated using the
infant’s weight at the start of prophylaxis as reported in
the RCTs [16,17]. Because no subsequent weight of
infants was reported in the trial, the infant weight needs
to be estimated at each month to correctly determine the
subsequent prophylaxis dose. Infant weight was estimated
using the UK-specific WHO growth chart data predicting
infant weight based on chronological age [19,20]. Bearing
in mind that the population in the model is a preterm
patient population, an adjustment is required to thechronological age to account for the preterm birth.
Gestational age at birth was used to derive corrected
chronological age, which is then used in conjunction
with the UK growth chart. The corrected chronological
age refers to the age at the start of administration
(as reported in two pivotal trials) adjusted to reflect the
gestational age at the birth; for example, an infant who is
20 weeks old at the start of administration but was born
at 30 wGA would have a corrected age of 10 weeks,
assuming a typical 40-week gestation. Regression methods
(ordinary least squares) were used to approximate the
relationship between weight (y) and chronological age (x),
using goodness of fit criteria. The resulting equation
y = 0.0083x3 - 1.9512x2 + 191.01x + 3869.4 was subse-
quently used to estimate the relative increase in infant
weight at monthly intervals. Average age and weight at
initiation of prophylaxis are shown in Table 2. In the base
case analysis, the correct dose was determined based on
the infant’s weight, and the number of 100-mg and/or
50-mg vials required to administer this dose were then
estimated and cost determined accordingly. Drug prices
were taken from the Monthly Index of Medical Specialities
(MIMS) and are UK-specific [27]. The RSV season is
assumed to last five months, and this also reflects the
duration of administration in both palivizumab RCTs [5,6].
Cost of RSV hospitalisation
The rate and length of hospital admissions in both the
general ward and ICU were estimated using data from
Feltes et al. for children with CHD [5,16], and the
IMPACT study for both preterm infants and children
with CLD [6,17]; however, the IMPACT study has insuffi-
cient data to determine if there is a difference in either the
rate of admissions to the ICU and paediatric ward or the
length of stay between the preterm subgroups or children
with CLD. Therefore, for the purposes of the model they
are assumed to be equal. The rate and length of hospital
admissions are shown in Table 1.
The cost per day of RSV hospitalisation is shown in
Table 1. Cost sources are UK-specific. Admitted patient
care costs were identified from the National Schedule of
Reference Costs (Trusts) 2009–2010 [28] and community
care costs were identified from Costs of Health and Social
Care 2009–2010 [29].
Table 2 Average age and weight at treatment initiation
Subgroup Post conception
age at birth (SE)





(upper and lower CI)
CHD babies§ 38.50 (0.10)‡ 26.60 (0.8) 25.10 6,649 (6,257; 7,041)
CLD babies 29.00 (0.11)‡ 23.12 (0.68) 14.13 4, 833 (4,084; 4,527)
Preterm: <29 wGA 29.00 (3.70†)‡ 15.40 (0.51) 4.40 3,709 (3,503; 3,915)
Preterm: 29–32 wGA 30.50 (3.89†)‡ 12.39 (0.34) 2.89 3,959 (3,804; 4,114)
Preterm: 33–35 wGA 34.00 (4.34†)‡ 10.89 (0.46) 4.89 4,306 (4,084; 4,527)
Abbreviations: CI Confidence interval, SE Standard error, CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age. * Calculated
assuming a normal gestation of 40 weeks; † Estimated assuming a confidence interval of ± 25%; ‡ Gamma distribution; § Data from Feltes et al. 2003 [4] or
MedImmune Data on File.
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The additional costs associated with the management of
sequelae (respiratory morbidity) were applied each year
to the proportion of patients suffering from these sequelae.
In the base case analysis, it was assumed that all infants
hospitalised with RSV disease would experience additional
respiratory sequelae (respiratory morbidity) related re-
source use for two years compared to non-admitted
infants. This is reflective of the cohort study by Greenough
et al. [24] and Shefali-Patel [22], which provided the mean
incremental resource use for this period for infants
with CLD and 33–35 wGA, respectively. Incremental
resource use for the mid preterms was extrapolated
from Greenough et al. [24]. Clinical contact costs were
derived from UK-specific Unit Costs of Health and Social
Care 2009–2010 [29] while the unit costs of days in
hospital were taken from the NHS National Schedule
of Reference Costs [28]. For the purposes of modelling,
a single cost input was used for respiratory sequelae-
associated resources. For the 33–35 wGA subgroup,
this cost was taken directly from Shefali-Patel et al. [22] at
£1,342 over two years; this figure was inflated to 2010
costs and halved to give an annual figure of £810. For all
other subgroups, a cost of £14,015 per patient per year
was used, calculated from the product of the units of
resource use and the associated unit costs (less the cost of
the initial RSV hospitalisation, omitted to avoid double
counting) reported by Greenough et al. [24]. This approach
and the resultant costs reflect those presented by Wang
et al. [13,14], however the alternative data source for the
33–35 wGA subgroup results in a significantly different
sequelae-associated determination of resources compared
to the other subgroups. It is uncertain if this difference is
due to an actual difference in the rate of sequelae between
subgroups or due to the methodologies used to capture
and report the resource use between the studies. Using the
lower figure for the 33–35 wGA subgroup is a conservative
assumption. A single cost input was used to avoid overesti-
mating the impact of individual cost components associ-
ated with respiratory sequelae in univariate (one-way)
sensitivity analysis.Quality of life
The health-related quality of life (HRQoL) values used in
the model are shown in Table 1 and assume a disutility
associated with RSV hospitalisation and respiratory sequelae
five years down the line. Utility data were obtained from
the study by Greenough et al. [21].
This retrospective study assessed HRQoL in infants 5
years of age who had previously been admitted to a
neonatal admissions service. This study administered
the multi-attribute Health Utilities Index Mark 2 (HUI2)
and HUI3 instruments to assess health status and HRQoL.
These instruments were sent to parents who were asked
to make an assessment of the child’s HRQoL over the
previous 4 weeks. Participants comprised 190 infants with
CLD and a median wGA of 27 weeks (range 22–33 weeks),
retrospectively identified as having stayed in a neonatal
admissions service. Of these 190 patients, 33 had proven
RSV infection. The HUI2 was originally developed for
paediatric application and clinical evaluation studies,
whereas HUI3 was developed for use in adults and
population surveys. As such, the utilities obtained using
the HUI2 measure has been used in the model over the
HUI3. For the purposes of the model, these same utilities
have been applied for the immediate RSV hospitalisation
and those associated with long-term sequelae. Since HRQoL
was assessed at five years of age in the Greenough et al.
study, the model conservatively assumes that the decre-
ment in HRQoL attributable to respiratory sequelae is also
only applied for a five-year period.Model validation
One-way sensitivity analysis
In the one-way (univariate) sensitivity analysis, all model
parameters were individually varied between their
minimum and maximum values, based on the 95%
confidence interval for all parameters, and the ICER
recorded. These results are presented in the form of a
tornado diagram; however, for simplicity only the 10
parameters that have the greatest impact on ICER vari-
ability are presented.
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PSA was performed using Monte Carlo simulation tech-
niques that allow all parameters to be varied simultan-
eously within a plausible range. The probability of RSV
hospitalisation, prophylaxis efficacy, and mortality were
given beta distributions. Beta distributions were also
applied to the baseline utility scores for RSV and non-RSV
hospitalisation. The estimation of the distribution ranges
was based on published data or, where unavailable, the
confidence interval was assumed to equal 25% of the
deterministic value and the standard errors were calculated.
All costs were assigned a gamma distribution, as this
takes into account the likely skew and variability with
these parameters. The lowest and highest prices per day
were used as estimates for the credible range and used to
estimate a standard error. For all other costs, the confidence
interval was assumed to equal 25% of the deterministic
value and the standard errors were calculated.
Other parameters include the number of prophylaxis
doses, which varied between three and six doses, the
duration to which to apply the incremental costs associated
with respiratory sequelae, varied between zero and five
years, and utility differences associated with respiratory
sequelae, varied between three and six years. A gamma
distribution was assigned to these parameters.
Results
Base case
Table 3 presents the base case results for the cost-
effectiveness analysis and shows the total costs and
QALYs associated with prophylaxis with palivizumab
and no prophylaxis based on hypothetical cohorts of
100 infants within each of the subgroups. Prophylaxis
against severe RSV infection results in ICERs of £33,216,
£19,168, £3,845, £30,205 and £99,056 per QALY for
high-risk infants with CHD, infants with CLD, premature
infants <29 wGA, premature infants 29–32 wGA, and
premature infants 33–35 wGA, respectively, compared
with no prophylaxis.Table 3 Summary of results per hundred infants from the
base case model
Palivizumab No prophylaxis
Costs QALYs Costs QALYs ICER
CHD infants £636,108 2,597 £449,120 2,591 £33,216
CLD infants £569,491 2,613 £440,816 2,606 £19,168
Preterm infants
<29 wGA £367,776 2,622.94 £354,226 2,619.42 £3,845
29-32 wGA £353,668 2,623.12 £272,481 2,620.43 £30,205
33-35 wGA £318,079 2,622.90 £73,621 2,620.43 £99,056
Abbreviations: CHD Congenital heart disease, CLD Chronic lung disease, wGA
weeks of gestational age, QALY Quality-adjusted life-year, ICER Incremental
cost-effectiveness ratio.One-way sensitivity analysis
Univariate sensitivity analysis demonstrates how the
ICER is affected by varying parameters through a range
of extremes, as illustrated in Figure 2. Depending on the
parameter altered, the ICER ranges from greater than the
accepted willingness to pay (WTP) threshold of £30,000
per QALY to dominant (clinically superior and cost saving).
The influence of two parameter types was common
across all subgroups: those affecting the number of
RSV hospitalisations (such as the underlying risk of RSV
hospitalisation, the efficacy of palivizumab prophylaxis,
and the duration of the RSV season) and those affecting
costs (such as the weight and/or age of infants at the
start of administration). Other significant drivers across
the subgroups include, to a varying degree, the cost of
managing respiratory sequelae, the number of years to
apply lower utility for or increased healthcare consumption
associated with sequelae, and the discount rate associated
with outcomes.
PSA
Table 4 shows the probability that the intervention is
cost-effective, based on the results of 5,000 Monte Carlo
simulations at a WTP threshold of £20,000 and £30,000
per QALY. While the cost acceptability of palivizumab may
be challenged at the £20,000 threshold, since all subgroups
have a less than 50% probability of being cost-effective, the
results are more favourable at the £30,000 threshold. The
associated cost-effectiveness acceptability curves (CEACs)
are shown in Figure 3. The CEAC curve plots the propor-
tion of simulations that will be cost-effective as the WTP
threshold is varied along a continuum.
Risk factors in the preterm infant’s 33–35 wGA subgroup
The model estimates an ICER of £99,056 per QALY for
preterm infants in the 33–35 wGA subgroup. While this
is higher than the level conventionally accepted by NICE
in the UK, it is plausible that a proportion of infants in
this subgroup (i.e. those most “at risk”) would benefit from
palivizumab prophylaxis. Therefore a further threshold
analysis was performed to investigate the impact of
considering additional RSV-hospitalisation risk factors.
Various clinical and environmental factors, such as the
number of siblings, male gender and parental smoking
[30-33], are known to increase the risk of RSV-
hospitalisation. However, individual patients may have
one or more of these factors and so considering them
in isolation would be of limited value. Furthermore,
there is considerable variance between data sources
regarding the prevalence of environmental risk factors
such as parental smoking, day care attendance and breast
feeding. Additionally, studies of interest vary in quality,
sample size, design and population investigated. Therefore,
it was deemed that the best approach in this threshold
Figure 2 Univariate sensitivity analysis of top 10 parameters by subgroup. a: preterm infants < 29 weeks. b: preterm infants 29–32 wGA.
c: preterm infants 33–35 wGA. d: CLD infants. e: CHD infants.
Table 4 Probability that palivizumab is cost-effective for
different WTP thresholds
Sub-group WTP threshold £20,000 WTP threshold £30,000
CHD 36.76% 51.52%
CLD 45.04% 60.06%
<29 wGA 45.02% 51.22%
29-32 wGA 30.44% 36.78%
33-35 wGA 2.8% 5.4%
Abbreviations: CHD Congenital heart disease, CLD Chronic lung disease, wGA
weeks of gestational age, WTP Willingness to pay.
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increasing the overall risk of RSV-hospitalisation and its
effect on the ICER.
Figure 4 shows the effect of baseline risk of RSV
hospitalisation on cost-effectiveness for preterm infants
33–35 wGA. The curve shows how varying the risk
affects the acceptability of the ICER. For instance, at a
WTP of £30,000/QALY, palivizumab prophylaxis is
cost-effective for an infant with an adjusted baseline
risk of RSV hospitalisation of at least 17.94%. Similarly,
prophylaxis is cost-effective at the £20,000/QALY
threshold if the risk of RSV hospitalisation is greater
than 22.23%.
Figure 3 Cost-effectiveness acceptability curves by subgroup. a: preterm infants <29 wGA. b: preterm infant’s 29–32 wGA. c: preterm infant’s
33–35 wGA. d: CLD infants. e: CHD infants.
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The results of this economic analysis have shown that
prophylaxis with palivizumab represents good use of
NHS resources for children at high risk of RSV-related
hospitalisation and its sequelae in the UK. Prophylaxis
with palivizumab is cost-effective in infants with CLD
or <29 wGA at cost/QALY of £19,168 and £3,845
respectively. Cost-effectiveness in 29–32 wGA preterm
and CHD infants was demonstrated at £30,205 and
£33,216 without additional risk factors being considered.
The slightly higher mean starting weight and age for CHDinfants resulting from the broader treatment eligibility
of ≤ 24 months compared to ≤ 6 months for preterm
infants led to higher prophylaxis costs, which likely
explains the ICER being greater than in other subgroups.
Cost/QALY of £99,056 was observed for 33–35 wGA
preterm infants; however, sensitivity analysis demonstrated
that prophylaxis becomes cost-effective at the £30,000
threshold in those at the highest risk of RSV hospital-
isation. The analysis shows that palivizumab would
represent a cost-effective use of NHS resources for a
vulnerable and important patient population. Similar
Figure 4 Effect of risk of RSV hospitalisation on cost-effectiveness for preterm infants 33–35 wGA.
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Calmette-Guérin (BCG) national immunisation programme
in the UK targeting infants most at risk of exposure to
tuberculosis [34].
Sensitivity analyses illustrated that subgroups are suscep-
tible to different parameter variations. However, common
drivers of cost-effectiveness included those affecting the
number of RSV hospitalisations and those affecting costs.
Unsurprisingly, the discount rate associated with outcomes
was identified as a significant factor for many scenarios,
due to the upfront cost of prophylaxis followed by a
prolonged health gain in the future. Historically, mortality
associated with RSV hospitalisation was identified as a key
parameter of uncertainty. While this is the case for some
subgroups in this analysis, it is not the case throughout
given the relatively low base case mortality rates assumed,
especially for the preterm infant groups.
Strengths and limitations
The main limitations of the study arose from the un-
certainty surrounding the epidemiology of RSV-associated
hospitalisation, mortality, and sequelae. RSV is not routinely
tested for across hospitals and, therefore, it is difficult to
gauge the true hospital burden and mortality rate associated
with the disease. Rates of RSV-associated respiratory
sequelae are also very difficult to ascertain. Increasing
retrospective studies suggest an association of severe RSV
infection with consequences such as asthma [9,35];
however, it is unclear whether this is a direct cause nor
whether RSV disease prevention will reduce such conse-
quences. Overall, further large, prospective, observational
studies would be beneficial for providing estimates of
RSV-associated rates of hospitalisation, mortality and
sequelae.
A key strength of this analysis is that it utilises updated
efficacy data derived from the IMPACT pivotal trial and
as much UK-specific data as possible. Furthermore, theanalysis is based on a set of conservative estimates, which
may underestimate the cost-effectiveness of palivizumab.
First, all infants are assumed to have received five doses of
palivizumab; however, infants born after the onset of the
RSV season would require fewer than five doses. In
addition, only costs borne by the health care sector, such
as medication costs and general practitioner and hospital
visits, were included in the analysis; the inclusion of
societal cost, such as costs due to out-of-pocket expenses
or lost productivity while the parent cares for the child, or
any RSV cases that required ambulatory care may contribute
to lower ICER results.
Previous evaluations
A recent systematic review has shown that ICERs vary
greatly from study to study, making it difficult for decision
makers to decide whether prophylaxis with palivizumab is
cost-effective [14]. Differences in populations, interventions,
perspectives, and time horizons have all contributed to
the discrepancies between studies. Wang et al. [13,14] and
Nuijten et al. [12] have reported the cost-effectiveness
of palivizumab from a UK perspective. Nuijten et al.
suggested that palivizumab may be cost-effective in pre-
term infants ≤ 35 wGA, infants with bronchopulmonary
dysplasia, and infants with CHD [12]. On the other hand,
Wang et al. reported that prophylaxis with palivizumab
does not represent good value when used unselectively
in preterm infants without CLD or infants with CLD or
CHD; however, it may be cost-effective (based on a
threshold of £30,000/QALY) for infants with CLD or
CHD when they have two or more additional risk factors
[14]. Several previous economic evaluations have attempted
to model the impact of risk factors for RSV hospitalisation
on cost-effectiveness [13,14]. Studies suggest an association
between hospitalisation with RSV and clinical/environmen-
tal risk factors such as gestational age, age at the com-
mencement of the RSV season, birth weight, gender,
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[14,32,33]. Some of these economic evaluations have used
methods for synthesising the risk factors into a single
model, which may introduce bias and complexity as they
combine multiple risk factors without consideration of
possible interactions between risk factors. In our eco-
nomic analysis, a threshold analysis has been developed
that considers the overall risk of RSV hospitalisation ra-
ther than attempting to identify the impact of specific
individual clinical and environmental risks factors them-
selves. This approach allows the demonstration of a
relationship between level of the baseline risk of RSV
hospitalisation and cost-effectiveness of palivizumab
irrespective of the specific combinations of risk fac-
tors. By relying on the overall risk of RSV hospitalisa-
tion, clinicians or decision makers are empowered to
use whichever risk factor assessment they deem ap-
propriate to estimate the baseline risk of RSV
hospitalisation.Conclusion
Using updated efficacy data derived from the pivotal
IMPACT trial, most recent healthcare costs, and mak-
ing conservative assumptions, the current analysis
demonstrates the cost-effectiveness of palivizumab ver-
sus no prophylaxis in infants at high risk of hospita-
lisation with RSV in the UK. Therefore, prophylactic
palivizumab represents an economically viable use of
NHS resources for infants (aged under 24 months)
with CHD, infants (aged under 24 months) with CLD
and preterm infants born at 32 wGA or below and pre-
term infants born 33–35 wGA when additional risk fac-
tors are considered.Competing interests
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